Endotracheal Intubations Articles & Analysis
2 news found
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. SNG001 demonstrated a favourable safety profile and was well ...
N8 Medical believes that use of the CeraShield™Endotracheal Tube may reduce this rate of mortality. “Biofilm growth on endotracheal tubes may lead to deadly secondary bacterial infections and exaggerated inflammatory responses requiring 8 to 9 days of additional mechanical ventilation. ...